







Anti-cancer potential of *Fasciola hepatica* extracts

Ferreira S¹, Fernandes R^{1,2}, Alves ^{3,4}, Richter J.⁵, Botelho M.C. ^{2,3}

1 Ciências Químicas e Biomoléculas, Escola Superior de Tecnologia da Saúde do Porto, Portugal., 2 i35, Instituto de Investigação e Inovação da Universidade do Porto, Portugal, 3 INSA, National Institute of Health Dr. Ricardo Jorge, Department of Health Promotion and Chronic Diseases, Porto, Portugal, 4 Fundação Professor Ernesto Morais, Porto, Portugal, 5 Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Germany

AIM

To investigate the oncogenic role of *F. hepatica* extracts.





BACKGROUND

•Fascioliasis is a food borne disease caused by infection with a liver fluke termed Fasciola (F.) hepatica. Fascioliasis, as a neglected tropical disease, commonly affects poor people from developing countries. It has been estimated that at least 2.6 million people are infected with fascioliasis worldwide.

•According to the International Agency for Research on Cancer, two other liver flukes Opistorchis viverrini and *Clonorchis sinensis*) have been recognized as definitive causes of cancer (IARC, 2012).

•On the other hand even long-lasting and/or repeated *F. hepatica* infections have not been associated with cancer, so far. There are any known causative associations between this parasite and cholangiocarcinoma or liver cancer.

METHODOLOGICAL STRATEGY

Chine Hamster Ovary (CHO) cells were treated with F. hepatica extracts and cell proliferation was assessed by using the indirect method for estimating cell number based on the mitochondrial dehydrogenase activity, which reduces sodium 2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt) with MTS cell proliferation reagent.

RESULTS

Surprisingly we observed unexpected death of CHO cells when treated with *F. hepatica* extracts.

Fig. 1: Fasciola haepatica life cycle.



Fig. 2: Cell proliferation assay of Fasciola haepatica and Schistosoma haematobium extracts-treated cells. The growth curve shows that treated cells with F. hepatica showed no growth while cells treated with S. haematobium proliferated significantly faster and more than control cells (Left panel). Trypan exclusion assay of control and F. hepatica and S. haematobium-treated cells. We confirmed the induced necrosis of CHO cells when treated with F. haepatica extracts and increase in cell viability when treated with S. haematobium extracts by trypan exclusion assay. (Right panel).

CONCLUSIONS

•We now hypothesize that some molecules contained in *F hepatica* extracts could have a potential as a preventive or even curative anti-cancer substance.